CD 4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study

@inproceedings{Kaufmann2003CD4T,
  title={CD 4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study},
  author={Gilbert R. Kaufmann and Luc Perrin and Guiseppe Pantaleo and Milos Opravil and Hansjakob Furrer and Amalio Telenti and Bernard Hirschel and Bruno Ledergerber and Pietro Vernazza and Enos Bernasconi and Martin Rickenbach and Matthias Egger and Manuel Battegay},
  year={2003}
}
Methods: Plasma HIV-1 RNA levels and CD4 and CD8 T-lymphocyte counts were longitudinally analyzed over 4 years in 2235 participants of the Swiss HIV Cohort, commencing HAART between 1996 and 1997. The CD4 Tlymphocyte count increase, the percentage of individuals with a CD4 T-lymphocyte count of 500/μL or greater and less than 200/μL, and the determinants of CD4 Tlymphocyte recovery were evaluated in individuals treated with continuous (CONT; n=985) and discontinuous (DISCONT; n=1250) HAART. 

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Durability and reasons for discontinuation of first highly active antiretroviral therapy (HAART) in a cohort of proteinase inhibitor naive HIV-infected patients

  • A Hänsel, H Bucher, R Nüesch, M. Battegay
  • J Acquir Immune Defic Syndr
  • 2001
Highly Influential
5 Excerpts

Prevalence of clinical and laboratory adverse events associated with potent antiretroviral therapy: Swiss HIV Cohort Study

  • J Fellay, K Boubaker, B Ledergerber
  • Lancet
  • 2001
Highly Influential
5 Excerpts

Cohort Study

  • PG Yeni, SM Hammer, CC Carpenter
  • 2001

Similar Papers

Loading similar papers…